---
title: ISPE Annual Meeting 2026
description: >-
  Meet Pedestal Health at ISPE 2026 in Milan, Booth 300. Bring your evidence
  questions.
date: '2026-08-29'
category: Events
canonical_url: https://www.pedestalhealth.com/resources/events/other/ispe-2026/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: ispe-2026
id: 3K9JHxn9T80BDX1Mz9RvAl
contentType: article
---

ISPE 2026 · Milan · Booth 300

# Bring your evidence questions to Booth 300

More endpoints, smaller populations, faster timelines, and evidence obligations that outlast approval.

We're building a continuous system for evidence generation to meet them, one that serves clinical, regulatory, and strategic decisions across the full lifecycle of care.


![ISPE 2026 event hero background](https://images.ctfassets.net/h4s3ip99qawo/1eizKn9Q3Fv3qgv7EmEdaM/a22337a6d457b68216faa2ece6690757/ispe-2026-event-background.png?w=1920&fm=webp&q=75)

## Presentations from Headwater Science at ISPE 2026

Our partners at Headwater Science are presenting new research on real-world methods and designs throughout the conference.





### Estimating recurrent complication burden under time-varying risk: a comparison of Poisson regression and the partitioned count estimator

**Poster · C-439**

*Wed 2 Sep · 12:00–1:30 PM CEST*

**Yasmmyn Salinas** · with Teresa Bufford, Derek Gazis, Julie Crawford, Kathleen Hurwitz, Alan Brookhart

This analysis draws on Pedestal Health's IBD cohort: 1,022 adults with Crohn's disease followed across anti-TNFα and alternative advanced therapies.



Built on Pedestal Health data. This analysis draws on Pedestal Health’s IBD cohort: 1,022 adults with Crohn’s disease followed across anti-TNFα and alternative advanced therapies.

The cohorts referenced here are managed under longstanding research protocols established by Pedestal Health (formerly Target RWE) and our academic partners. Protocol names including TARGET-IBD appear in published literature and are referenced where relevant for scientific accuracy.


- [View Page →](/resources/events/other/ispe-2026-poster-c-439/) 

### When can we ignore informative censoring?

**Podium · 2A-02**

*Mon 31 Aug · 3:45–4:00 PM CEST*

**Nuvan Rathnayaka** · with Alan Brookhart, Kathleen Hurwitz


- [View Page →](/resources/events/other/ispe-2026-podium-2a-02/) 

### Effect of varying pre-interruption periods on interrupted time series estimates and interpretation: a simulation study

**Spotlight Poster · B-284**

*Tue 1 Sep · 11:30 AM–1:00 PM CEST*

**Rachel Faller** · with Nuvan Rathnayaka


- [View Page →](/resources/events/other/ispe-2026-poster-b-284/) 

### Regional and variant-era variation in treatment patterns and remdesivir use among immunocompromised patients hospitalized with COVID-19: an analysis of polypharmacy using UpSet plots

**Poster · C-123**

*Wed 2 Sep · 12:00–1:30 PM CEST*

**Kayla Hendrickson** · with Nuvan Rathnayaka, Mark Berry (Gilead), Carrie Nielson (Gilead), Alan Brookhart, Kathleen Hurwitz


- [View Page →](/resources/events/other/ispe-2026-poster-c-123/) 

### Standard error estimation for transported effects in sequential nested trial emulations using M-estimation

**Poster · C-350**

*Wed 2 Sep · 12:00–1:30 PM CEST*

**Catie Wiener** · with Chase Latour, Jeanny Wang, Paul Zivich, Alan Brookhart


- [View Page →](/resources/events/other/ispe-2026-poster-c-350/) 

### Fake world data, real world problems: simulations for the pharmacoepidemiologist

**Workshop · SW-2G**

*Mon 31 Aug · 5:15–6:45 PM CEST*

**Catie Wiener, Alexander Breskin, Amarnath Marthi** · with Chase Latour


- [View Page →](/resources/events/other/ispe-2026-workshop-sw-2g/) 

## Schedule a meeting

Tell us what you're working on and we'll hold a time to talk at Booth 300.



By submitting, you consent to Pedestal Health contacting you about this request and related work.

*Interactive embed: Pardot Form.*

Pedestal Health works with Headwater Science at every stage of evidence generation, drawing on its methods, technology, and causal inference expertise. That partnership runs through comparative effectiveness studies requiring dynamic treatment design, regulatory-grade external control work, methodological consultation on submission packages, and the bias-protection frameworks that consequential evidence increasingly requires.


- [Visit Headwater Science](https://www.headwaterscience.com)